---
title: 'Regulatory Daily Summary: What Happened on November 17, 2026'
headline: FDA rejects Summit’s ivonescimab application over survival benefit
description: The agency approved Gazyva, Klygefa and Wilserdly, while Australia cleared
  a chemotherapy-risk test and the UK launched a women’s health program.
url: https://thebench.bio/news/regulatory/2026-11-17
topic: regulatory
date: '2026-11-17'
covers:
- '2026-11-17'
date_published: '2026-11-17T12:02:52Z'
date_modified: '2026-11-17T12:02:52Z'
tags:
- Regulatory
sources: 8
publisher: TheBench.Bio
---

# Regulatory Daily Summary: What Happened on November 17, 2026

**FDA rejects Summit’s ivonescimab application over survival benefit**

The agency approved Gazyva, Klygefa and Wilserdly, while Australia cleared a chemotherapy-risk test and the UK launched a women’s health program.

## Today in brief

The FDA rejected Summit Therapeutics’ ivonescimab application for previously treated EGFR-mutated lung cancer, saying progression-free survival alone did not establish a favorable benefit-risk profile without a statistically significant overall-survival gain. [1] [2] [3] The FDA approved Roche’s Gazyva for primary membranous nephropathy and AstraZeneca’s Klygefa for generalized myasthenia gravis. [4] Roche’s Wilserdly received FDA approval, adding the company to the oral selective estrogen receptor degrader market. [5]

The UK regulator launched a Women’s Health Programme after a review found pregnant women represented in 1.1% of UK trial applications from 2019 to 2023, and breastfeeding women in 0.6%. [6] [7] Australia approved Yourgene Health’s test for variants that may signal risk of severe reactions to 5-fluorouracil. [8]

## FDA turns down ivonescimab without significant survival benefit

The FDA sent Summit Therapeutics a complete response letter declining ivonescimab with chemotherapy for previously treated, locally advanced or metastatic non-small cell lung cancer with EGFR mutations. [1] [2] [3] The agency said progression-free survival improvement did not establish a favorable benefit-risk profile without a statistically significant overall-survival gain. [2] [3]

In the Phase 3 HARMONi trial, median progression-free survival was 6.8 months with ivonescimab and chemotherapy, compared with 4.4 months with chemotherapy alone. [3] Median overall survival was 16.8 months versus 14.0 months, but the primary analysis was not statistically significant. [3] [4] A longer-follow-up analysis of Western participants found a hazard ratio for death of 0.78, with a nominal P value of .0332. [3]

Summit said it would continue developing ivonescimab, which Akeso developed and which is approved in China but not in Summit’s licensed territories, including the United States and Europe. [2] [3] [4] The FDA had indicated that overall-survival improvement would be required for US approval in this patient group. [1]

## FDA approves Gazyva for kidney disease and Klygefa for myasthenia gravis

The FDA approved Roche’s Gazyva to induce proteinuria remission in adults with primary membranous nephropathy who face a risk of disease progression. [4] In the Phase 3 MAJESTY study, complete remission at two years occurred in 36.1% of patients taking Gazyva and 5.7% taking tacrolimus. [4]

The FDA also approved AstraZeneca’s Klygefa for adults with anti-AChR antibody-positive generalized myasthenia gravis. [4] Patients use gefurulimab once a week through a subcutaneous autoinjector. The Phase 3 PREVAIL study showed improvement over placebo by week one. [4]

## Also worth knowing

- Australia’s Therapeutic Goods Administration approved Yourgene Health’s Insight DPYD assay for clinical testing. It detects 19 variants that may help identify patients at elevated risk of serious reactions to 5-fluorouracil. Southern Cross Diagnostics will market and supply it. [8]
- The UK Medicines and Healthcare products Regulatory Agency launched its Women’s Health Programme to address evidence gaps and examine how medicine and device risks and benefits may differ for women. Its review of 4,616 trial applications from 2019 to 2023 found pregnant women included in 1.1% and breastfeeding women in 0.6%. [6] [7]
- The FDA approved Roche’s Wilserdly, making the company a participant in the oral selective estrogen receptor degrader market. [5]

## The day in numbers

- **16.8 vs. 14.0 months**: Median overall survival in HARMONi for ivonescimab plus chemotherapy versus chemotherapy alone. The difference was not statistically significant in the primary analysis. [3] [4]
- **1.1% and 0.6%**: Shares of UK trial applications from 2019 to 2023 that included pregnant women and breastfeeding women, respectively. [6] [7]
- **19 variants**: Number of DPYD variants detected by the newly approved Australian assay. [8]

## Also published

- [There and Back Again: Patent Office Reverts to PTAB Control over IPR Petitions](<https://patentdocs.org/2026/11/16/there-and-back-again-patent-office-reverts-to-ptab-control-over-ipr-petitions/>), Patent Docs
- [Summit shares fall as FDA rejects closely watched PD-1/VEGF drug](<https://www.biopharmadive.com/news/summit-akeso-fda-ivonescimab-reject-egfr-lung-cancer/874745/>), BioPharma Dive

## Sources

1. [FDA holds Summit to survival bar in ivonescimab CRL](<https://www.biocentury.com/article/661634/fda-holds-summit-to-survival-bar-in-ivonescimab-crl?utm_source=bc_rss&utm_medium=rss>), BioCentury, 2026-11-17
2. [FDA rejects Summit’s ivonescimab application for lung cancer](<https://www.pharmaceutical-technology.com/news/fda-rejects-summits-ivonescimab-application/>), Pharmaceutical Technology, 2026-11-16
3. [FDA Rejects Summit’s PD-1×VEGF Bispecific Ivonescimab in EGFR-Mutated NSCLC, Citing Lack of Survival Benefit](<https://www.biopharminternational.com/view/fda-rejects-summit-s-pd-1-vegf-bispecific-ivonescimab-in-egfr-mutated-nsclc-citing-lack-of-survival-benefit>), BioPharm International, 2026-11-16
4. [The BioPharm Brief: FDA Rejects Ivonescimab, Gazyva Becomes the First Approved pMN Therapy, and a Nanobody Approval in Myasthenia Gravis](<https://www.biopharminternational.com/view/the-biopharm-brief-fda-rejects-ivonescimab-gazyva-becomes-the-first-approved-pmn-therapy-and-a-nanobody-approval-in-myasthenia-gravis>), BioPharm International, 2026-11-16
5. [Roche joins the oral SERD club as FDA clears Wilserdly](<https://pharmaphorum.com/news/roche-joins-oral-serd-club-fda-clears-wilserdly>), pharmaphorum, 2026-11-17
6. [MHRA launches new programme to tackle evidence gaps on women’s health ](<https://www.gov.uk/government/news/mhra-launches-new-programme-to-tackle-evidence-gaps-on-womens-health>), MHRA, 2026-11-16
7. [MHRA launches initiative to improve female participation in trials](<https://www.clinicaltrialsarena.com/news/mhra-launches-initiative-to-improve-female-participation-in-trials/>), Clinical Trials Arena, 2026-11-17
8. [Yourgene wins Australian approval for chemotherapy toxicity screening assay](<https://pharmafile.com/news/yourgene-wins-australian-approval-for-chemotherapy-toxicity-screening-assay/>), Pharmafile, 2026-11-17

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.biocentury.com/article/661634/fda-holds-summit-to-survival-bar-in-ivonescimab-crl?utm_source=bc_rss&utm_medium=rss>
[2]: <https://www.pharmaceutical-technology.com/news/fda-rejects-summits-ivonescimab-application/>
[3]: <https://www.biopharminternational.com/view/fda-rejects-summit-s-pd-1-vegf-bispecific-ivonescimab-in-egfr-mutated-nsclc-citing-lack-of-survival-benefit>
[4]: <https://www.biopharminternational.com/view/the-biopharm-brief-fda-rejects-ivonescimab-gazyva-becomes-the-first-approved-pmn-therapy-and-a-nanobody-approval-in-myasthenia-gravis>
[5]: <https://pharmaphorum.com/news/roche-joins-oral-serd-club-fda-clears-wilserdly>
[6]: <https://www.gov.uk/government/news/mhra-launches-new-programme-to-tackle-evidence-gaps-on-womens-health>
[7]: <https://www.clinicaltrialsarena.com/news/mhra-launches-initiative-to-improve-female-participation-in-trials/>
[8]: <https://pharmafile.com/news/yourgene-wins-australian-approval-for-chemotherapy-toxicity-screening-assay/>
